Stelara sales were flat at $2.45 billion in the first quarter and came in below expectations of $2.6 billion, according to LSEG data. J&J has struck deals to delay U.S. launches of close-copy versions of Stelara until 2025, a key patent for which expired last year. Analysts have said the delayed competition will make the drug a larger contributor for J&J's 2024 and 2025 revenue than previously anticipated. Read this story